Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer (Q40359028)
Jump to navigation
Jump to search
scientific article published on 10 May 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer |
scientific article published on 10 May 2010 |
Statements
1 reference
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer (English)
1 reference
Razelle Kurzrock
1 reference
Roy S Herbst
1 reference
S Gail Eckhardt
1 reference
Scot Ebbinghaus
1 reference
Peter J O'Dwyer
1 reference
Michael S Gordon
1 reference
William Novotny
1 reference
Meredith A Goldwasser
1 reference
Tanyifor M Tohnya
1 reference
Bert L Lum
1 reference
Avi Ashkenazi
1 reference
Adrian M Jubb
1 reference
David S Mendelson
1 reference
10 May 2010
1 reference
1 reference
2839-2846
1 reference
Identifiers
1 reference